首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression
【24h】

Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression

机译:血清Rock2,miR-300和miR-450b-5p水平在多发性硬化的两种不同临床表型中:与患者残疾和疾病进展相关

获取原文
获取原文并翻译 | 示例
           

摘要

Relapsing remitting multiple sclerosis (RRMS) is the most prevalent MS subtype. Years after disease onset, most of RRMS patients show transition into secondary progressive form (SPMS). Currently, no biomarkers are available for tracking disease progression. Here, we observed marked elevation of Rho-associated protein kinase 2 (ROCK2) along with significant downregulation of miRNAs 300 and 450b-5p expressions in the serum of 39 RRMS and 35 SPMS Egyptian patients compared to healthy controls. More pronounced alterations were found in SPMS versus RRMS patients. Our findings also suggest relations between elevated ROCK2 and reduced expression of both miRNAs with the degree of disability and disease progression. Notably, these biomarkers effectively discriminated RRMS from SPMS patients with miR-450b-5p showing the highest prognostic power.
机译:复发缓解型多发性硬化症(RRMS)是最常见的MS亚型。在发病数年后,大多数RRMS患者表现为向继发性进展型(SPMS)过渡。目前,没有生物标记物可用于追踪疾病进展。在这里,与健康对照组相比,我们观察到39例RRMS和35例SPMS埃及患者血清中Rho相关蛋白激酶2(ROCK2)显著升高,miRNAs 300和450b-5p表达显著下调。与RRMS患者相比,SPMS患者的变化更为明显。我们的研究结果还表明ROCK2升高和两种miRNA表达降低与残疾程度和疾病进展之间存在关系。值得注意的是,这些生物标记物有效地区分了RRMS和SPMS患者,其中miR-450b-5p显示出最高的预后能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号